台灣臨床試驗主持人資料庫|TPIDB

2018-12-15 - 2022-09-27

Phase II

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer

Condition/Disease

Non-small Cell Lung Cancer
Test Drug

M7824

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

沈佳儀

Taipei Veterans General Hospital

Division of Thoracic Medicine

2018-07-18 - 2021-08-31

Phase II

A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)

Condition/Disease

Non-small Cell Lung Cancer
Test Drug

tepotinib

Participate Sites
6Sites

Recruiting2Sites

Terminated4Sites

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

2015-02-01 - 2017-06-30

Phase II

A MULTIPLE-CENTER, RANDOMIZED, PARTIALLY DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTIVIRAL EFFECTS OF 12-WEEK TREATMENT WITH RO6864018 IN VIROLOGICALLY SUPPRESSED ENTECAVIR TREATED PATIENTS WITH HEPATITIS B VIRUS INFECTION

Condition/Disease

HEPATITIS B VIRUS(HBV) INFECTION
Test Drug

RO6864018

Participate Sites
2Sites

Terminated2Sites

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

2014-12-30 - 2019-12-31

Phase III

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)

Condition/Disease

major adverse cardiovascular event, MACE
Test Drug

Epanova®

Participate Sites
7Sites

Terminated6Sites

江晨恩

Taipei Veterans General Hospital

賴文德

Kaohsiung Municipal Gangshan Hospital

未分科

2016-06-01 - 2019-05-31

Phase I

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors

Condition/Disease

Advanced Tumors
Test Drug

BGB-A317

Participate Sites
6Sites

Terminated6Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

侯明模

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-03-14 - 2025-05-13

Phase II

An Open-Label, Multicenter, Global Phase 2 Basket Study of for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Entrectinib Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Condition/Disease

Locally Advanced or Metastatic Solid Tumors that Entrectinib Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Test Drug

Entrectinib

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

羅永鴻

Taipei Veterans General Hospital

2015-08-01 - 2017-12-31

Phase I

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study To evaluate The Safety, Tolerability, And Immunogenicity Of INO-1800 Alone Or in Combination With INO-9112 Delivered IM Followed By Electroporation In Select Nucleos(t)ide Analogue-Treated, HBeAG-Positive, Chronic Hepatitis B Patients

Condition/Disease

Chronic Hepatitis B
Test Drug

INO-1800 and INO-9112

Participate Sites
6Sites

Terminated5Sites

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

莊萬龍

Kaohsiung Municipal Gangshan Hospital

未分科

2016-02-15 - 2019-12-31

Phase II

A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).

Condition/Disease

Non-small Cell Lung Cancer
Test Drug

HM61713

Participate Sites
6Sites

Terminated6Sites

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

2016-12-01 - 2021-05-31

Phase I/II

A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Treatment-Naïve (locally advanced) or Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

Condition/Disease

Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
Test Drug

Margetuximab

Participate Sites
3Sites

Terminated3Sites

趙毅

Taipei Veterans General Hospital

Digestive System Department

2018-10-24 - 2021-12-31

Phase I/II

Open-Label, Multicenter Study of D07001-Softgel Capsules (Oral Gemcitabine Hydrochloride) in Subjects With Unresectable, Metastatic or Locally Advanced Gastrointestinal (GI) Cancer in Dose-Escalation Phase and in Subjects With Advanced Biliary Tract Cancer (BTC) Following Primary Chemotherapy or Combined Chemoradiotherapy (CCRT) in Dose-Expansion Phase

Condition/Disease

Advanced Biliary Tract Cancer (BTC)
Test Drug

D07001-Softgel Capsules

Participate Sites
5Sites

Terminated4Sites

陳明晃

Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源

China Medical University Hospital-Taipei

未分科

Search Result

List